ScripThe end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Immatics Gets $150m Up Front For Rights